# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

> **NCT01827982** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-54861911 1mg
- **DRUG:** JNJ-54861911 3 mg
- **DRUG:** JNJ-54861911 9 mg
- **DRUG:** JNJ-54861911 27 mg
- **DRUG:** JNJ-54861911 81 mg
- **DRUG:** JNJ-54861911 160 mg
- **DRUG:** JNJ-54861911 tbd
- **DRUG:** JNJ-54861911 9 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01827982
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827982, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01827982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*